Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· February 25, 2026

Stocks Settle Higher as AI Disruption Fears Ease

View original at nasdaq.com
Stocks Settle Higher as AI Disruption Fears Ease The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.77%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.76%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.09%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • New AI tools for Claude Cowork agent software are to integrate rather than displace existing systems

    80% confidence

  • Threatened to raise the global tariff rate to 15%

    80% confidence

  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by +4.6%

    80% confidence

  • S&P earnings growth expected to climb by +8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth

    80% confidence

  • Saw a good chance of a diplomatic solution to the standoff over Iran's nuclear program

    80% confidence

  • 10 to 15 days was pretty much the maximum he would allow for negotiations to continue

    80% confidence

  • Interest rates are likely to remain unchanged for some time as recent economic data show an improvement in the labor market, while inflation risks remain

    80% confidence

  • Considering a limited military strike on Iran to ramp up pressure on the country to strike a deal over its nuclear program

    80% confidence

  • I remain optimistic that there can be more rate cuts this year, but that hinges on seeing actual progress on inflation that shows we are on a path back to 2%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com